Research Article

Pharmacokinetics of Transdermal Flunixin Meglumine Following a Single Dose in Marine Toads (*Rhinella marina*)

Gregory Scott, Meghan M. Louis, Julie A. Balko, Claire M. Bublitz, Brigid V. Troan, Ronald E. Baynes, Dustin Smith, and Larry J. Minter

1. Introduction

There is growing evidence to support the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for analgesia in amphibians, including flunixin meglumine, meloxicam, and ketoprofen among others [1–6]. NSAIDs act by antagonizing cyclooxygenase (COX) enzymes that activate the inflammatory cascade by converting arachidonic acid into prostaglandins [7]. The same mechanism is supported in an amphibian model using meloxicam. In North American bullfrogs (*Lithobates catesbeianus*) that underwent mild surgical trauma, an intramuscular injection of meloxicam suppressed the production of prostaglandin E2 (PGE2) [4]. Studies have also shown that NSAIDs provide clinically effective analgesia in amphibians. Indomethacin and ketorolac administered by subcutaneous injection produced mild analgesic effects in northern leopard frogs (*Lithobates pipiens*) [2]. Compared to saline controls, treated frogs had...
an increased nociceptive threshold in response to an acetic acid test, where increasing concentrations of acetic acid are applied topically as a noxious stimulus until the animal exhibits a response. Acetic acid tests have also shown that flunixin meglumine administered by intracoelemic injection provides analgesia in leopard frogs [1]. Analgesia has been demonstrated in African clawed frogs (Xenopus laevis) treated with subcutaneous flunixin meglumine, assessed by both an acetic acid test and the Hargraves tests, the latter of which exposes the animal’s limbs to a thermal noxious stimulus, and latency withdrawal times are recorded [3, 6].

Despite the established therapeutic benefit of NSAIDs, the small body size and sensitive skin of amphibians creates challenges for safe handling and delivery of injectable or oral medications. The permeability of amphibian skin, however, offers a unique opportunity for transdermal drug absorption following topical administration. The skin is a major interface of gas, water, and electrolyte exchange for many amphibians, and any drug applied to the skin has potential for systemic uptake [8, 9]. For amphibians, recommendations are available for transdermal use of multiple classes of therapeutics including antibiotics, antifungals, antiparasitics, anesthetics, analgesics, and nutritional supplements [9]. However, absorption of topically applied drugs can be variable [5]. While there are reports of their usage, few drugs have pharmacokinetic studies to support transdermal absorption in amphibians [10–13]. Only one study has evaluated plasma concentrations following topical application of the NSAIDs ketoprofen and meloxicam; however, neither was formulated for transdermal delivery [5].

In 2017, a novel transdermal formulation of flunixin meglumine was approved by the US Food and Drug Administration for use in cattle for the control of pain and fever. Studies in cattle have shown that this formulation is rapidly absorbed and effective for reducing lameness, cortisol, and PGE2 in inflammatory exudates [14–17]. Given the usefulness of topical therapy in amphibians, the targeted nature of this drug for topical use, and the effectiveness of this formulation in at least one species, investigation of transdermal flunixin meglumine for use in amphibians is warranted.

The objective of this study was to examine the pharmacokinetics of this newly available transdermal flunixin meglumine formulation in healthy marine toads (Rhinella marina) following a single topical dose. Our hypothesis was that flunixin meglumine would be rapidly absorbed and reach peak plasma concentrations consistent with those recommended for therapy in cattle.

2. Materials and Methods

This study was approved by the Institutional Care and Use Committee of North Carolina State University, IACUC ID# 19–614. Twenty-one adult marine toads of undetermined sex and a median (range) weight of 117 g (84.5–206.5 g) were enrolled in the study. The toads were wild-caught as part of a routine invasive species management program from a free-ranging feral population on the grounds at a zoological institution in Miami, Florida, USA. A subset of animals was approved by the Zoo Miami Research Committee to be transferred to the North Carolina Zoo in Asheboro, North Carolina (NC Zoo), for use in this study. Prior to transfer, all animals were individually identified with subcutaneous passive integration transponders. Upon arrival at the NC Zoo, the animals were divided and housed in four separate tubs (178.8 × 81.28 × 35.56 cm) with access to hide boxes and a shallow pool of reconstituted reverse osmosis water. The tanks were cleaned daily and disinfected weekly. The animals were kept at room temperature without supplemental heating or cooling. Humidity was not measured. The light cycle was maintained according to the working hours of the animal husbandry staff (8:00 am–5:00 pm). Animals were group fed approximately 10 crickets (gut-loaded and dusted with calcium powder) per toad for five consecutive days per week. All animals were allowed a 6-day acclimation period and determined to be healthy based on a physical exam by a veterinarian prior to the study. Animals did not receive any other medical treatments during the study.

On the study day, a target dose of 3.3 mg/kg transdermal flunixin meglumine (Banamine Transdermal, Merck Animal Health, Madison, New Jersey 07940, USA) was administered topically to each toad on the midpoint of the dorsum (Figure 1). The dose was chosen based on the treatment recommendation for cattle [14, 16]. Higher doses (25–50 mg/kg) previously reported in frogs were avoided due to renal pathology and mortalities associated with those treatments [3, 6]. Each animal was individually removed and weighed just prior to being treated. The animals were briefly manually restrained to ensure consistent drug placement. Due to small dose volumes, each dose was measured and administered with a 5–20 μL micropipette (Fisher Scientific, Waltham, Massachusetts 02451, USA). All toads were placed in a separate tub following treatment and restricted from having access to water for a minimum of 4 hours following drug administration. If samples beyond 4 hours were required, toads were returned to their original tub and given access to shallow water below the level of the dorsum for the remainder of the study.

The toads were randomly divided [18] into three groups (n = 7/group) for timing of blood collection. Each group had blood collected at two different timepoints from the following: 1, 2, 4, 8, 12, and 24 h after flunixin meglumine administration. This approach represents a sampling method according to a population pharmacokinetic matrix using sparse sampling technique to minimize handling required for multiple sample collections on each animal [19]. Each toad was manually restrained for blood collection. Blood was collected from the popliteal sinus using a 27-gauge needle and syringe and immediately transferred to a lithium heparin blood tube. All blood samples were centrifuged, and plasma was separated into cryovials and stored at −80°C within 1 hour (h) of collection. Total blood sampling did not exceed 1% body weight for each animal for the duration of the study. Once all samples were collected, frozen samples were transported to North Carolina State University College of Veterinary Medicine for flunixin meglumine quantification.
Plasma was analyzed by liquid chromatography (UPLC/MS/MS) utilizing a BEH Phenyl 1.7 µm 2.1 × 100 mm column. Drug standards (Sigma Aldrich, St. Louis, Missouri 63103, USA) for flunixin meglumine were >99% purity. Corrections were made for the meglumine salt in flunixin prior to standards being developed. The UPLC/MS/MS method was validated using blank plasma from toads. For extraction, plasma samples were thawed and processed using a solid phase extraction (SPE), and 50 µL of each sample was combined with 250 µL of 4% phosphoric acid in ultrapure water. Samples were vortexed and then transferred to an Oasis Prime HLB 1cc Cartridge (Waters Corp., Milford, Massachusetts 01757, USA). The samples were processed with the nitrogen positive pressure manifold (Biotage, Charlotte, North Carolina 28269, USA). Each sample was washed with 1 mL of 5:95 methanol:ultrapure water and eluted with 0.5 mL of 60:40 acetonitrile:ultrapure water +0.1% formic acid. The samples were then filtered through 0.2 µm PTFE Whatman Mini-UniPrep syringe filter devices and analyzed by UPLC/MS/MS. The injection volume for all samples was 5 µL. Validation standards were prepared over a linear range and were used to construct calibration curves. The standard curve concentrations ranged from 0.5 ng/mL to 10,000 ng/mL. The limit of quantification (LOQ) was 1 ppb, and the limit of detection (LOD) was 0.5 ppb, which was the lowest concentration on the calibration curve. The column temperature was 35°C, the sample temperature was ambient, and the run time was 5 minutes.

Pharmacokinetic analysis of drug concentration versus time profiles was performed with Phoenix WinNonlin software (version 8.0; Certara, Princeton, NJ, 08540 USA). A noncompartmental analysis of sparse samples was used to derive the slope of the terminal phase (λz; h) and the half-life (t1/2; h). The area under the plasma concentration–time curve from time zero to infinity (AUC0—∞; h × µg/mL) was calculated by the linear trapezoidal rule. The volume of distribution (per fraction absorbed) (Vd/F; ml/kg) and clearance per fraction absorbed (Cl/F; ml/h/kg) were also determined, and values for maximum concentration (Cmax; µg/mL) and time to maximum concentration (Tmax; h) were taken directly from the data. Population pharmacokinetic analysis was attempted using Phoenix NLME. The NLME attempts yielded similar parameter estimates to the noncompartmental analysis, but due to limited data and high shrinkage, the variability would not have been fully represented, so it does not provide any more information than noncompartmental analysis.

Three toads were euthanized at 48 h, and nine toads were euthanized 8-9 days after flunixin meglumine treatment; complete necropsies were performed, and tissues were fixed in 10% neutral buffered formalin. Tissues were processed routinely for evaluation by light microscopy by a board-certified veterinary pathologist. For the first three toads, two sections of skin each from the treated and untreated areas as well as liver and kidney were examined. In the remaining 9 toads, two sections of skin each from the treated and untreated areas and drink patch, along with brain, lung, heart, liver, kidney, spleen, gastrointestinal tract, and gonad, were evaluated.

3. Results

Transdermal flunixin meglumine was administered successfully to all 21 toads. No animals displayed any adverse responses or effects during the study. All blood samples were collected without difficulty with the exception of one toad at the 1 h timepoint at which blood could not be collected. A scatter plot of the plasma flunixin meglumine concentrations of each toad with a line plot of the mean values over time is presented in Figure 2. The pharmacokinetic parameters are presented in Table 1.

On necropsy, no gross lesions attributable to flunixin meglumine treatment were appreciated in any of the toads. Histologically, one toad had an approximately 1000 µm diameter, well-demarcated section of skin showing superficial epidermal necrosis with clefting through the stratum spinosum to above the stratum basale, dissociation of cells within the remaining epidermis, and a mild lymphoplasmacytic junctional infiltrate. This was interpreted as minimal, focal, superficial epidermal necrosis, consistent with topical injury. However, this finding could not be confidently attributed to the topical flunixin meglumine as other possibilities such as an insect bite or direct injury from the pipette tip could not be ruled out. No further histologic lesions potentially attributable to treatment were observed in the skin or organs of any of the other 11 toads examined.

4. Discussion

Data from the current study indicate that topically applied transdermal flunixin meglumine at 3.3 mg/kg is rapidly absorbed in marine toads. The mean maximum plasma concentration (Cmax) in marine toads is more than 5-fold that of dairy cattle also administered 3.3 mg/kg [14, 16]. A follow-up study determined that in cattle with induced...
lameness, transdermal flunixin meglumine at 3.3 mg/kg improved lameness scores, reduced plasma cortisol concentration, reduced coronary band temperature, and increased pain tolerance threshold compared to untreated animals [17]. In goats, transdermal flunixin meglumine at 3.3 mg/kg resulted in a $C_{\text{max}}$ of 0.134 $\mu$g/mL and a 50% reduction from baseline of plasma PGE2 concentration [20]. As $C_{\text{max}}$ in the current study was nearly 50 times greater (6.31 $\mu$g/mL), one could hypothesize that this dosing in marine toads would be associated with similar indicators of effective analgesia.

Time to reach maximum plasma concentration ($t_{\text{max}}$) in toads was 1 h, which is faster than dairy cattle, goats, and pigs [14, 16, 20, 21]. Furthermore, it should be noted that the current study failed to observe the absorption phase as the first sampling time (1 h) yielded the highest mean concentration. Thus, plasma concentrations likely reached a higher $C_{\text{max}}$ at a time point sooner than 1 h, but it was not detected by this sampling protocol. With the rapid plasma uptake, it is likely that resulting analgesic effects occur quickly as well. Based on these results, future studies into the analgesic effects of transdermal flunixin in amphibians are warranted as it may provide rapid clinical analgesia without the need for injection.

The plasma elimination half-life ($t_{1/2}$) in toads (2.79 h) was relatively short compared to 6- to 8-week-old dairy calves administered a single dose (6.42 h) or adult dairy cattle administered multiple doses (5.20 h) of transdermal flunixin meglumine [14, 16]. However, plasma concentrations may not reflect pharmacodynamic effects. With NSAIDs, this may be due to binding within tissues or to the COX enzyme, as suspected with flunixin meglumine in dogs [22]. In African clawed frogs administered injectable flunixin meglumine, analgesic effects lasted for as long as 24 h following treatment, although plasma concentrations were not measured [3, 6]. Further study is warranted into the analgesic effects and duration of transdermal flunixin meglumine in amphibians.

The topical administration method used in the current study was easily accomplished and likely less painful for the animals than using an injectable technique. Topical administration was rapid and required a less extensive and shorter period of restraint than would be required for injection, making topical administration arguably less stressful. Although animals in the current study were briefly restrained to ensure consistency of drug administration, in a clinical setting, it would likely be possible to treat most animals without any manual restraint.

Consistent transdermal absorption for different drugs and among different species of amphibians should not be assumed. In one study, injectable ketoprofen or meloxicam was applied topically to smoky jungle frogs (Lep todactylus pentadactylus) resulting in remarkably different pharmacokinetic profiles. Ketoprofen was well absorbed, yielding plasma concentrations consistent with analgesia in other species, while meloxicam was undetectable [5]. Considering this example of inconsistent absorption for different injectable, nontransdermal formulations, expanding the use of drugs formulated for transdermal absorption may offer more effective topical therapeutics for amphibians.

In dogs, treatment with flunixin meglumine has been associated with gastrointestinal (GI) side effects and mucosal ulceration [23, 24]. More severe GI perforations have occurred in flunixin meglumine-treated dogs that had concurrent conditions, such as dehydration and/or GI parasites, or those that were treated concurrently with corticosteroids [22]. GI side effects have also been seen in equids treated with flunixin meglumine [25]. Renal pathology has been appreciated in multiple bird species treated with flunixin meglumine [26]. Despite these effects in other species, no clinical adverse effects or systemic histopathologic lesions were observed in the current study. A topical reaction was appreciated in only one of 12 toads examined, and that lesion was small, restricted to the superficial epidermis, and not clearly related to the flunixin meglumine. In cattle, mild topical reactions including damaged hairs, flaky and thickened skin were seen 3 to 7 days after dosing. The reactions were considered cosmetic and resolved without treatment [27]. In general, transdermal flunixin meglumine

![Figure 2: Semilogarithmic plot of all plasma flunixin meglumine concentrations following topical administration (3.3 mg/kg) in marine toads ($n = 21$). The line plot represents the average values at each timepoint.](image-url)
at 3.3 mg/kg appeared safe for marine toads, but animals should be monitored for development of dermal reactions. The effect of multiple doses of transdermal flunixin meglumine is unknown and warrants investigation.

There are limitations in pharmacokinetic studies, such as this one, where the number of available samples is restricted due to the animals’ small size or intolerance for repeated handling. The technique of pooling samples has been used in similar studies [5], but while this is beneficial for small-sized animals where sample volume is limited, it ignores the variance among individuals. A population-based pharmacokinetic approach using sparse sampling is limited by not representing all animals at each sampling timepoint; however, sources of variability among each animal remain represented within the data. The sparse sampling method was effective in providing a safe method for pharmacokinetic investigation of a small species in the current study. It should be considered as an alternative to pooling samples if the animals’ size allows a large enough sample for processing.

Housing these animals as a group may have provided a source of absorption variability. Following treatment, some toads were occasionally seen in physical contact with other toads. It is feasible that this may have allowed for additional drug absorption from one toad to another. In cattle, flunixin absorption was lower if animals were allowed access to other cows and licking of drug from the application site occurred. However, this did not prevent absorption of an effective dose and did not require dose adjustment [27]. Based on the data, there is no clear evidence group housing affected absorption in toads, either from individual outliers or evidence of additional absorption events. In clinical use, best practice may be to isolate animals for a period time immediately following treatment until there was no residue of the drug on the treated animal.

5. Conclusion

Based on the results of the current study, a single topical dose of transdermal flunixin meglumine at 3.3 mg/kg is rapidly absorbed in marine toads with minimal adverse effects. Comparisons to recent studies in domestic ruminants suggest the dose administered and plasma concentrations achieved in this study may be consistent with effective analgesia if marine toads follow a similar trend. The permeability of amphibian skin provides an advantageous route for topical therapy, especially in small species that are difficult to medicate by injectable or oral routes. Future studies should evaluate multiple dose pharmacokinetics and confirm safety, as well as analgesic effects of transdermal flunixin meglumine. A population-based pharmacokinetic approach using sparse sampling techniques can be useful for future amphibian pharmacokinetic studies, including those investigating transdermal therapeutics.

Data Availability

The full data set which was used for this research is available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

G. Scott, M. M. Louis, J. A. Balko, B. V. Troan, R. E. Baynes, D. Smith, and L. J. Minter contributed to the study concept and design. G. Scott, M. M. Louis, and L. J. Minter contributed to sample collection. C. M. Bublitz, B. V. Troan, and R. E. Baynes contributed to data collection and analysis. D. Smith contributed to husbandry and animal care. All authors are responsible for interpretation of the data. All authors drafted this article or revised it critically for important intellectual content. All authors gave final approval of the version of this article to be published. All authors agreed to be accountable for all aspects of this work.

Acknowledgments

The authors thank Danielle Mzyk for her inspiration to investigate transdermal therapeutics in novel species. They also thank Heather Scott, Kelly Tardif, Amy Koepp, Emma Houck, Alissa Mones, Ty Smith, and Amber Lee for their contributions to sample collection, processing, and animal care. This project was funded by the North Carolina Zoo.

References


